Back to Search
RICHARD KERBEL, M.D.
M.D.
Pediatric Adolescent Medicine Physician
NPI: 1356390215Individual
Specialties, Licenses & Credentials
Pediatric Adolescent Medicine PhysicianPrimary
Pediatrics — Adolescent Medicine
Code: 2080A0000X
45421(MA)
Research & Publications (20)
A role for the TGFbeta-Par6 polarity pathway in breast cancer progression.
PMID 19667198·Proc Natl Acad Sci U S A·2009
7-preclinical
The multiple personality disorder phenotype(s) of circulating endothelial cells in cancer.
PMID 19406208·Biochim Biophys Acta·2009
6-review
Tumor-associated fibroblasts as "Trojan Horse" mediators of resistance to anti-VEGF therapy.
PMID 19111874·Cancer Cell·2009
8-other
Dose-dependent increases in circulating TGF-alpha and other EGFR ligands act as pharmacodynamic markers for optimal biological dosing of cetuximab and are tumor independent.
PMID 19276250·Clin Cancer Res·2009
7-preclinical
Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy.
PMID 19671869·Clin Cancer Res·2009
6-review
Effective treatment of advanced human melanoma metastasis in immunodeficient mice using combination metronomic chemotherapy regimens.
PMID 19622578·Clin Cancer Res·2009
7-preclinical
Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis.
PMID 19249681·Cancer Cell·2009
7-preclinical
Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR.
PMID 19234131·Proc Natl Acad Sci U S A·2009
7-preclinical
Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib.
PMID 18443598·Br J Cancer·2008
7-preclinical
Endothelial progenitor cells are cellular hubs essential for neoangiogenesis of certain aggressive adenocarcinomas and metastatic transition but not adenomas.
PMID 18715995·Proc Natl Acad Sci U S A·2008
7-preclinical
Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth.
PMID 18199548·Cancer Res·2008
7-preclinical
Long-term progression and therapeutic response of visceral metastatic disease non-invasively monitored in mouse urine using beta-human choriogonadotropin secreting tumor cell lines.
PMID 18852148·Mol Cancer Ther·2008
7-preclinical
Development of a preclinical model of spontaneous human melanoma central nervous system metastasis.
PMID 18559492·Cancer Res·2008
7-preclinical
A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients.
PMID 18362940·Br J Cancer·2008
8-other
Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study.
PMID 18202416·J Clin Oncol·2008
3-trial
An eosinophil immune response characterizes the inflammatory skin disease observed in Tie-2 transgenic mice.
PMID 18443190·J Leukoc Biol·2008
7-preclinical
Pharmacology of the novel antiangiogenic peptide ATN-161 (Ac-PHSCN-NH2): observation of a U-shaped dose-response curve in several preclinical models of angiogenesis and tumor growth.
PMID 18381955·Clin Cancer Res·2008
7-preclinical
Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents.
PMID 18772115·Cancer Cell·2008
7-preclinical
Phosphorylated epidermal growth factor receptor on tumor-associated endothelial cells is a primary target for therapy with tyrosine kinase inhibitors.
PMID 18472966·Neoplasia·2008
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 548 MOUNT AUBURN ST
WATERTOWN, MA 02472 - Phone
- (617) 923-1040
Quick Facts
- NPI
- 1356390215
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile